What is the evidence regarding the use of cannabis for mental health disorders?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Cannabis Should Not Be Used for Mental Health Disorders

The current evidence does not support the use of cannabis or cannabinoids for treating mental health disorders, and substantial evidence demonstrates significant psychiatric harms, particularly with THC-containing products. 1, 2, 3

Key Evidence Against Use

Psychiatric Risks Clearly Documented

The most recent guidelines and systematic reviews consistently demonstrate that cannabis use, particularly THC-predominant products, poses serious mental health risks:

  • Psychosis: Cannabis use in early youth is associated with elevated risk for psychotic disorders in adulthood, with estimates ranging from 2-fold to 11-fold increased risk depending on frequency and potency 1, 3

  • Depression and Suicidality: Cannabis use is associated with higher risk for depression and suicidal ideation or behavior, particularly when initiated in adolescence 1

  • Bipolar Disorder: THC-predominant cannabis worsens mania symptoms and function in those with bipolar disorder 3

  • Cannabis Use Disorder: Approximately 10% of adults with chronic cannabis use develop cannabis use disorder, with clinically significant impairment 2. Among those with past-year cannabis use, about 3 in 10 have cannabis use disorder 3

  • Exacerbation of Existing Disorders: Cannabis may exacerbate psychiatric disorders in vulnerable individuals 2

Limited and Insufficient Evidence for Benefits

The 2026 systematic review and meta-analysis found 4:

  • Anxiety: Some reduction in anxiety symptoms (SMD=-0.40), but evidence came predominantly from secondary outcomes in studies of other conditions, with very low certainty
  • Depression: Trivial-to-no effect (SMD=-0.20) with very low certainty
  • PTSD: One small trial (n=20) showed benefit, but insufficient to recommend
  • Cannabis Use Disorder: Cannabinoids actually worsened severity in one RCT (SMD=2.35)
  • Other disorders: No benefit demonstrated for ADHD, psychosis, or Tourette syndrome

The 2022 American Journal of Psychiatry review concluded there are no FDA-approved psychiatric indications for cannabinoids and limited evidence supporting therapeutic use for psychiatric disorders 5.

Specific High-Risk Populations to Avoid

Cannabis use should be completely avoided in 3:

  1. Adolescents and young adults (highest risk for psychosis, CUD, and neurodevelopmental harm)
  2. Individuals with bipolar disorder (worsens mania)
  3. Individuals with psychotic spectrum disorders (increases psychotic symptoms)
  4. Pregnant and breastfeeding individuals (negative effects on fetal brain development, premature birth risk) 1
  5. Those at risk for substance use disorders
  6. Older adults (higher risk for anxiety, depression, sedation, and cardiovascular events) 1

The Cannabidiol (CBD) Exception

There is emerging low-certainty evidence that pure CBD alone (not cannabis products) may reduce anxiety in patients with anxiety disorders 3. However:

  • Doses ≥300 mg/day carry risk of reversible liver enzyme abnormalities 2
  • The only FDA-approved CBD product (Epidiolex) is for specific epilepsy syndromes, not psychiatric conditions 1
  • Most commercially available "CBD" products contain variable amounts of THC and lack quality control

Clinical Pitfalls to Avoid

  1. Do not accept patient reports of "self-medication" as evidence of efficacy - associations may reflect shared risk factors or bidirectional relationships 6

  2. High-potency products are particularly dangerous - THC concentrations have nearly doubled from 9% (2008) to 17% (2017), with concentrates reaching 70% THC 1. High doses of THC are associated with psychosis 1

  3. Recognize cannabis use disorder symptoms: Using more than expected, difficulty cutting back, clinically significant impairment 2

  4. Monitor for withdrawal: Irritability, restlessness, anxiety, sleep disturbances, appetite changes, abdominal pain (occurs within 3 days of cessation, lasts up to 14 days) 2

  5. Counsel about driving impairment - cannabis users are more than twice as likely to be involved in motor vehicle crashes 2

What to Recommend Instead

Given the lack of efficacy and substantial risks, clinicians should:

  • Actively counsel patients against cannabis use for mental health conditions
  • Screen for cannabis use in all patients with mental health disorders, as use is common and modifiable
  • Offer evidence-based treatments for the specific psychiatric condition
  • If patients are already using cannabis, provide education about risks and offer treatment for cannabis use disorder if present
  • Consider pure CBD (pharmaceutical grade, with liver enzyme monitoring) only for anxiety disorders in research settings or after failure of evidence-based treatments, avoiding doses ≥300 mg/day 2

The evidence is clear: cannabis is not medicine for mental health disorders - it is a risk factor that worsens outcomes 3, 6.

References

3
Research

Cannabis and Mental Health: A Review.

JAMA internal medicine, 2026

5
Research

Risks and Benefits of Cannabis and Cannabinoids in Psychiatry.

The American journal of psychiatry, 2022

Related Questions

Should individuals with a personal or family history of psychotic disorders, severe anxiety, or depression use THC, and what are the recommended dosage limits and monitoring guidelines?
Can marijuana use cause bipolar disorder?
Does cannabis use worsen depression and anxiety?
Can THC edibles be addictive and lead to cannabis use disorder?
For an adult with anxiety and trauma undergoing EMDR, is cannabis appropriate and what dosing, THC/CBD limits, and safety considerations should be followed?
What proportion of patients with spinal cord injury have sleep apnea, and is this prevalence higher than in the general adult population?
How should I taper a patient on brexpiprazole (Rexulti) 2 mg who needs to switch due to insomnia to lurasidone (Latuda)?
How should I manage a symptomatic 48‑year‑old female with normal sinus rhythm at 90 bpm, rare ectopic beats, and two brief episodes of supraventricular tachycardia (paroxysmal atrial tachycardia) lasting up to 16 beats?
Will an MRI of the cervical spinal cord help determine if a steroid injection is appropriate?
For an adult with a 25‑hydroxy‑vitamin D level of 29.7 ng/mL and no contraindications, can I prescribe cholecalciferol (vitamin D3) 400 IU daily?
What is the appropriate management for a patient with normal sinus rhythm (average rate 70 bpm), rare ectopy, two episodes of monomorphic non‑sustained ventricular tachycardia lasting up to ten beats, frequent supraventricular tachycardia episodes consistent with premature atrial tachycardia lasting up to ten seconds, and symptoms occurring only during sinus rhythm?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.